Table 4.

Results of clinical trials of new treatment options for HCV

References	Formula of therapy	Number of patients (genotype)	Duration of treatment (weeks)	SVR (%)
Kwo et al. (SPRINT-1) [33, 34]	PegIFN-α-2b 1.5 μg/kg per week (P) + RBV 800-1,400 mg/day (R)	104 (G1)	48	38
	4 weeks of P/R lead-in followed by P/R + Boc 800 mg TID for 24 weeks	103 (G1)	28	56
	4 weeks of P/R lead-in followed by P/R + Boc 800 mg TID for 44 weeks	103 (G1)	48	75
	P/R/Boc for 28 weeks	107 (G1)	28	55
	P/R/Boc for 48 weeks	103 (G1)	48	67
	P/low-dose R (400–1,000 mg/day)/Boc	59 (G1)	48	36
McHutchison et al. [36] (PROVE1)	PR48 control: PegIFN-α-2a(P)/RBV (R)	75 (G1)	48	41
	T12PR12: T/P/R for 12 weeks	17 (G1)	12	35
	T12PR24	79 (G1)	24	61
	T12PR48	79 (G1)	48	67
Hezode et al. [37] (PROVE2)	T12PR24: T/PegIFN-α-2a(P)/RBV (R) for 12 weeks, followed by P/R for 12 more weeks	81 (G1)	24	69
	T12PR12: T/P/R for 12 weeks	82 (G1)	12	60
	T12P12: T/P for 12 weeks	72 (G1)	12	36
	PR48 control	82 (G1)	48	46
Lalezari et al. [46]	R7128 1,500 mg bid/180 μg PegIFN-α-2a/1,000–1,200 mg RBV	11 (G1)	4	45% RVR
Sulkowski et al. [54]	albIFN 900 μg q2wk + RBV	442 (G1)	48	48.2
	albIFN 1,200 μg q2wk + RBV	440 (G1)	48	47.3
	PegIFN alpha-2a 180 μg + RBV	441 (G1)	48	51.0
Nelson et al. [55]	albIFN 900 μg q2wk + 800 mg RBV	(G2/3)	24	79.8
	albIFN 1,200 μg q2wk + 800 mg RBV	(G2/3)	24	80.0
	PegIFN alpha-2a 180 μg + 800 mg RBV	(G2/3)	24	84.8
Shiffman et al. [70]	Nitazoxanide (NTZ)/pegIFN/RBV	42 (G1)NR	24	7% cEVR
	Placebo/pegIFN/RBV	22 (G1)NR	24	0% EVR
Bacon et al. [71]	NTZ/pegIFN/RBV	75 (G1)	48	60% cEVR
	Placebo/pegIFN/RBV	37 (G1)	48	49% cEVR
Rossignol et al. [68]	NTZ 500 mg twice daily	23 (G4)	24	30.4
	Placebo	24 (G4)	24	0
Rossignol et al. [69]	PegIFN/RBV	40 (G4)	48	45
	NTZ 12 weeks followed by NTZ/pegIFN 36 weeks	40 (G4)	48	47.5
	NTZ 12 weeks followed by NTZ/pegIFN/RBV 36 weeks	40 (G4)	48	62.5
Inoue et al. [75]	IFN-α-2b 10 MU × 3/week	44 (G1)	24	31.8
	IFN-α-2b 10 MU × 3/week + cyclosporin A 100–200 mg/day	76 (G1)	24	55.2

Boc boceprevir, T telaprevir